An Expanded Pneumococcal Vaccine (Prevnar 13) for Infants and Children
The FDA has licensed a 13-valent conjugate pneumococcal vaccine (PCV13; Prevnar 13 – Pfizer) for
the prevention of invasive pneumococcal disease (IPD) in infants and children <6 years old. It replaces
Prevnar (PCV7). An unconjugated 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 – Merck) is FDA-approved for use in adults....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: An Expanded Pneumococcal Vaccine (Prevnar 13) for Infants and Children
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1345
Article Code: 1345c
Date: August 23, 2010
Volume: 52
Pages: 67-68
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1345
Article Code: 1345c
Date: August 23, 2010
Volume: 52
Pages: 67-68
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)